1. Introduction
Sleep is a complex behavioral state that occupies one-third of the human life span. Although viewed as a passive condition, sleep is a highly active and dynamic process. Sleep was considered to be primarily important for restoration of brain function. However, to date, there is increasing evidence that sleep also modulates the metabolic, endocrine and cardiovascular systems [Trenell, 2007; Boethel, 2002; Knutson & Van Cauter, 2007; Knutson, 2008]. It is known that if left untreated, sleep disorders can have significant impact on daytime function, including learning, memory, attention, and behavior. The approach to the treatment of these disorders (whether with or without pharmacotherapy) is dependent on a thorough evaluation of the sleep complaint and accurate diagnosis. Previous studies reported a consistent difference between diabetic and non-diabetic subjects in the number of sleep disturbances per hour, indicating possible influence of diabetes on sleep pattern [Resnick, 2003; Kawakami, 2004]. Several studies have shown that patients with T2DM sleep less than the general population [Vgontzas, 2000; Buxton, 2010]. A gradual decrease in self-reported sleep duration seems to have developed over the same period as the dramatic increase in the incidence of obesity and diabetes, including a close relationship between sleep cycle and diabetes [Van Cauter, 1997; Spiegel, 2005; Chasens, 2007; Knutson & Van Cauter, 2008]. Sleeping disorders related to T2DM include insomnia, restless leg syndrome, periodic leg movement disorder, excessive daytime sleepiness, sleepwalking, nightmares, narcolepsy, and SDB, especially SA.
T2DM and SDB/SA are both prevalent diseases that share several risk factors, including advanced age and obesity [Tishler, 2003; Young, 1993]. T2DM is associated with higher incidence of cardiovascular, cerebrovascular, and renal diseases. There is also mounting evidence that SDB/SA is an independent risk factor for cardiovascular and cerebrovascular diseases. Interest in a potential independent link between the two diseases continues to grow.
2. Sleep loss
Chronic sleep loss is increasingly common in industrialized countries. The sleep impairment may result from various common disturbances, such as insomnia and OSA and may lead to striking changes in metabolic and endocrine functions [Spiegel, 1999]. Chronic sleep loss is a potential risk factor for obesity, insulin resistance, and T2DM.
Previous studies reported that both short (<6 hours) and long (>8 hours) sleepers as well as those with sleep loss, are at greater risk for glucose intolerance and T2DM [Sridhar & Madhu, 1994; Scheen, 1997; Ayas, 2003; Mallon, 2005; Gottlieb, 2005; Mallon, 2005; Yaggi, 2006; Chaput, 2007; Nakajima, 2008].
3. Sleep apnea
SA is a sleep disorder characterized by pauses in breathing during sleep. There are several forms of SA, but the obstructive type is the commonest. In OSA, pauses in breathing are caused by a physical block to airflow, usually in the oropharynx. OSA is usually defined by interruptions of airflow of at least 10-second duration (apneas), or by a decrease in airflow of at least 10 seconds (hypopneas) followed by blood oxygen desaturation and arousal (brief arousal associated with airway opening and resumption of breathing) [Report of American Academy of Sleep Medicine Task Force, 1999; Masood & Phillips, 2000].
3.1. Symptoms
SA is often first noticed by the bed partner who witness episodes of apneas or is suspected based on history of habitual snoring and/or excessive daytime sleepiness, general fatigue or near-miss car accidents. Other symptoms reported by patients with SA include [Bresnitz, 1994; Gupta, 2010; Wickwire & Collop, 2010] 1) irritability, 2) poor memory, 3) morning headache, 4) depression, 5) mood changes, 6) sexual dysfunction, and 7) nocturia.
3.2. Diagnosis
SDB/SA is often diagnosed by an overnight cardiorespiratory test called polysomnography [Jafari & Mohsenin, 2010]; though other simpler methods are currently available, such as type 3 cardiopulmonary monitoring [Collop, 2007]. The recorded signals are analyzed for the numbers of apneas and hypopneas, episodes of oxygen desaturation, as well as lowest oxygen saturation, average oxygen saturation, and time at desaturation <90% in minutes of the total bedtime for the entire night. Apnea is defined as a decrease in the amplitude of the airflow or respiratory effort signal to <10% of the baseline lasting at least 10 seconds. Hypopnea is defined as a decrease in the airflow or respiratory effort to <70% of the baseline for at least 10 seconds accompanied by >4% fall in oxygen saturation. The apnea-hypopnea index (AHI) is defined as the number of apneas/hypopneas per hour of sleep time. The latter is measured from the recorded signals of the electroencephalogram (averaged brain activity), electrooculogram (eye movements) and nuchal muscles electromyogram. An AHI of 5 establishes the diagnosis of SDB/SA. OSA is defined as absence of airflow in the presence of chest wall and/or abdominal excursions. The severity of SA is based on the AHI, and classified as mild (AHI ≥5 to <15), moderate (AHI ≥15 to <30), and severe (AHI ≥30), according to the guidelines of the American Academy of Sleep Medicine Task Force [Report of American Academy of Sleep Medicine Task Force, 1999].
3.3. Clinical features
Obese patients with OSA have short and wide neck, large tongue, and excess pharyngeal soft tissues. Significant SA is present in 40% of obese individuals, and 70% of OSA patients are obese [Vgontzas AN, 1994; Resta O, 2001; Daltro C, 2007]. Not only excess weight but also fat distribution, i.e. intra-abdominal fat accumulation, plays a major role in the development of OSA [Shinohara, 1997; Schäfer, 2002; Vgontzas, 2003]. A recent study of Japanese patients with T2DM found that BMI and waist circumference (WC) were the strongest predictors of the severity of SDB [Kashine, 2011]. OSA is independently associated with insulin resistance, T2DM and hypertension [Idris, 2009]. Several reports found high incidence of SA in both Japanese [Katsumata, 1991] and Caucasian [Einhorn, 2007] diabetic patients.
3.4.Treatment
There are several options for treatment of SA [Rosenberg & Doghramji, 2009]. These include:
3.4.1. Lifestyle changes
Weight loss, especially visceral fat reduction through caloric diet and exercise, should be recommended for all overweight patients with SA. Avoidance of alcohol and sleeping pills is often beneficial.
3.4.2.Oral devices
Oral devices such as dental appliances have been used with some success to maintain an open airway during sleep [Ng, 2005].
3.4.3.Nasal Continuous Positive Airway Pressure (nCPAP)
Nasal continuous positive airway pressure (nCPAP) is the golden standard treatment of SA in which a mask is worn over the nose and/or mouth whilst sleeping. The mask is attached to a machine that delivers a continuous stream of compressed air. The positive pressure pneumatically maintains an open airway during sleep. Treatment of OSA is reported to improve daytime sleepiness and various other clinical features of Sa including insulin responsiveness [Hassaballa, 2005; Harsch, 2004].
3.4.4. Surgery
Surgery may be considered in some cases, particularly those with tonsillar and adenoidal hypertrophy, narrow nasal airways, or facial deformities such as small jaw, nasal polyp or deviated nasal septum [Sundaram, 2005; Lojander, 1996; Holty, 2010].
4. Type 2 diabetes and sleep apnea
SDB/SA is often observed in patients with T2DM, and known to be potentially associated with atherosclerosis, leading to ACVDs. The International Diabetes Federation (IDF) Taskforce on Epidemiology and Prevention [Shaw, 2008] stated that the pathophysiological consequences of hypoxemia and sleep fragmentation might be involved in the development of insulin resistance and pancreatic -cell dysfunction through various biological mechanisms, such as direct effects of 1) intermittent hypoxia/desaturation and hypoxemia, 2) sympathetic nervous system activation (catecholamine) [Prabhakar & Kumar, 2010; Esler & Eikelis, 2006], 3) systemic inflammation (tumor necrosis factor-alpha [TNF-], interluokin-6 [IL-6], high sensitivity C-reactive protein [hsCRP] and monocyte chemoattractant protein 1 [MCP-1]) [Drager, 2010; Sahlman, 2010; Romero-Corral, 2010], 4) hypothalamic-pituitary-adrenal dysfunction (cortisol) [Follenius, 1992; Henley, 2009; Vgontzas & Chrousos, 2002], 5) dysregulation of adipocytokines (plasminogen activator inhibitor-1 [PAI-1], adiponectin) [Lam, 2008], 6) sleep architecture [Wang & Teichtahl, 2007] and 7) other factors. Both SDB/SA and T2DM are strongly associated with ACVD [Bradley & Floras, 2009] (Figure 1).
5. Type 2 diabetes mellitus and sleep-disordered breathing / sleep apnea: Role of adipocytokines
Both T2DM and SDB/SA have been linked to the metabolic syndrome based on visceral fat accumulation, with clustering of hyperglycemia, intra-abdominal fat accumulation, hypertension, hypertriglyceridemia, and hypo-high-density-lipoprotein-cholesterolemia [Rasche, 2010; Lui & Ip, 2010]. There is a broad overlap between the presumed mechanisms of that link T2DM and SDB/SA and features of the metabolic syndrome (Syndrome X) [Reaven, 1993], which is also known as “Syndrome Z” [Wilcox, 1998].
In addition to the localization and functional properties of visceral fat, experimental evidence links certain molecules in visceral fat to human disorders, especially insulin resistance and ACVD. An important question relates to the profile of molecules or genes expressed in subcutaneous and visceral fat. In order to answer this question, our group in collaboration with the human body map project team investigated the gene expression profile in human adipose tissue. This tissue had been traditionally regarded as a passive storage of excess energy in the form of triglycerides. Unexpectedly, we found that adipose tissues, especially visceral fat, abundantly express genes that encode secretory proteins including complement factors in the immune system, growth factors, and cytokines, most of which are important bioactive substances [Maeda, 1997; Matsuzawa, 2004]. We found PAI-1 [Shimomura, 1996] and HB-EGF [Matsumoto, 2002] in human visceral and subcutaneous fat cDNA library. Excess visceral fat overproduces and secretes PAI-1, which in turn increases the risk for thrombotic disorders [Shimomura, 1996]. Thus, it seems that visceral fat is directly linked to ACVD. Adipose tissue also produces a variety of the bioactive substances conceptualized as ‘adipocytokines’ [Funahashi, 1999; Matsuzawa, 2010]. Through systematic analysis of adipose tissue-expressed genes, we discovered a novel gene, designated adipose most abundant gene transcript 1 (apM1), for an adipocyte-derived secretory protein [Maeda, 1996], which was later named ‘adiponectin’. At the same time, using different approaches, adiponectin was identified independently by three other groups, as adipocyte complement-related protein of 30 kDa (ACRP30) [Scherer, 1995], adipoQ [Hu, 1996], and gelatin binding protein of 28 kDa (GBP28) [Nakano, 1996]. Adiponectin is specifically expressed in the adipose tissue [Arita, 1999]. The molecule has two domains, namely a collagen-like fibrous domain and a C1q-like globular domain. The single molecules combine and form a high-ordered structure [Arita, 1999]. Adiponectin binds to collagens I, III, and V, which are present in the subendothelial intima [Okamoto, 2000]. In fact, adiponectin adheres to endothelium-injured arterial walls [Okamoto, 2000]. This is the reason why we named this protein ‘adiponectin’ [Arita, 1999]. Numerous experimental studies found that adiponectin has anti-atherosclerotic [Ouchi, 2003] and insulin sensitivity properties [Han, 2009].
The production and secretion of adipocytokines are dynamically regulated by nutritional status. Over-eating and physical inactivity result in visceral fat accumulation, which leads to visceral fat dysfunction and dysregulated production of adipocytokines (overproduction of offensive adipocytokines, such as PAI-1, TNF-, HB-EGF and angiotensinogen, and underproduction of defensive adipocytokines, such as adiponectin), a state we call adipotoxicity. These changes are probably the major underlying mechanisms of lifestyle-related diseases [Kishida, 2011].
Daytime hypoadiponectinemia and nocturnal falls in circulating adiponectin concentrations in OSA patients with abdominal obesity, are in part, due to hypoxic stress [Nakagawa, 2008 & 2011]. A high frequency of SDB was identified in Japanese patients with poorly controlled T2DM, who also had intra-abdominal obesity with nocturnal dysregulated production of adiponectin [Kashine, 2010]. Obese East and South Asians including Japanese have a mild degree of adiposity, compared with European and American subjects [Wulan, 2010; Fujimoto, 1999; Tong, 2007; Kadowaki, 2006]. Unlike total body fat, body fat distribution, especially excess accumulation of visceral fat, correlates with various diabetogenic, atherogenic, prothrombotic and proinflammatory metabolic abnormalities in Japanese (referred to as the metabolic syndrome), that increase the risk of ACVD [Fujioka, 1987; Matsuzawa, 1994].
6. Conclusion
It is necessary to diagnose SDB from the standpoint of prevention of ACVD in diabetic patients. Weight reduction, particularly reduction of visceral fat, intensive glucose-lowering therapy, nCPAP therapy, or the combination of these therapies, have beneficial effects on the outcome of T2DM patients with SDB through improvement of dysregulated production of adipocytokines and SDB-related ACVD.
Acknowledgments
This work was supported in part by a Grant-in-Aid for Scientific Research No. (C) No. 21591177.
References
- 1.
Trenell M. I. et al. 2007 Sleep and metabolic control: waking to a problem? .34 1-2 1 9 - 2.
Boethel C. D. 2002 Sleep and the endocrine system: new associations to old diseases.8 6 502 505 - 3.
Knutson K. L. Van Cauter E. 2008 Associations between sleep loss and increased risk of obesity and diabetes.1129 287 304 - 4.
Knutson K. L. et al. 2007 The metabolic consequences of sleep deprivation. .11 3 163 178 - 5.
H.E. Resnick, et al.; Sleep Heart Health Study. Diabetes and sleep disturbances: findings from the Sleep Heart Health Study. .26 3 702 709 - 6.
Kawakami N. et al. 2004 Sleep disturbance and onset of type 2 diabetes. .27 1 282 283 - 7.
Vgontzas A. N. et al. 2000 Sleep apnea and daytime sleepiness and fatigue: relation to visceral obesity, insulin resistance, and hypercytokinemia. .85 3 1151 1158 - 8.
O.M. Buxton, et al. (2010) Sleep restriction for 1 week reduces insulin sensitivity in healthy men. Diabetes.9 59 2126 2133 - 9.
Van Cauter E. et al. 1997 Roles of circadian rhythmicity and sleep in human glucose regulation. .18 5 716 738 - 10.
K. Spiegel, et al. 2005 Sleep loss: a novel risk factor for insulin resistance and Type 2 diabetes. Journal of Applied Physiology.5 99 2008 2019 - 11.
Chasens E. R. 2007 Obstructive sleep apnea, daytime sleepiness, and type 2 diabetes. Diabetes Educator.33 3 475 482 - 12.
Knutson K. L. Van Cauter E. 2008 Associations between sleep loss and increased risk of obesity and diabetes.1129 287 304 - 13.
P.V. Tishler, et al. (2003) Incidence of sleep-disordered breathing in an urban adult population: the relative importance of risk factors in the development of sleep-disordered breathing. The Journal of American Medical Association.17 289 2230 2237 - 14.
Young T. et al. 1993 The occurrence of sleep-disordered breathing among middle-aged adults. .328 17 1230 1235 - 15.
Spiegel K. et al. 1999 Impact of sleep debt on metabolic and endocrine function.354 9188 1435 1439 - 16.
Sridhar G. R. Madhu K. 1994 Prevalence of sleep disturbances in diabetes mellitus. .23 3 183 186 - 17.
Scheen A. J. et al. 1996 Relationships between sleep quality and glucose regulation in normal humans. .271 2 Pt 1),E261 E270 - 18.
Ayas N. T. et al. 2003 A prospective study of self-reported sleep duration and incident diabetes in women. .26 2 380 384 - 19.
Mallon L. et al. 2005 High incidence of diabetes in men with sleep complaints or short sleep duration: a 12-year follow-up study of a middle-aged population. .28 11 2762 2767 - 20.
Gottlieb D. J. et al. 2005 Association of sleep time with diabetes mellitus and impaired glucose tolerance. .165 8 863 867 - 21.
Mallon L. et al. 2005 High incidence of diabetes in men with sleep complaints or short sleep duration: a 12-year follow-up study of a middle-aged population. .28 11 2762 2767 - 22.
Yaggi H. K. et al. 2006 Sleep duration as a risk factor for the development of type 2 diabetes. .29 3 657 661 - 23.
J.P. Chaput, et al. (2007) Association of sleep duration with type 2 diabetes and impaired glucose tolerance. Diabetologia.11 50 2298 2304 - 24.
Nakajima H. et al. 2008 Association between sleep duration and hemoglobin A1c level. .9 7 745 752 - 25.
Anonymous. 1999 Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. The Report of an American Academy of Sleep Medicine Task Force. .22 5 667 689 - 26.
Masood A. Phillips B. 2000 Sleep apnea. .6 6 479 484 - 27.
Bresnitz E. A. et al. 1994 Epidemiology of obstructive sleep apnea. .16 2 210 227 - 28.
Gupta R. K. et al. 2010 Obstructive sleep apnoea: a clinical review. .58 438 441 - 29.
Wickwire E. M. Collop N. A. 2010 Insomnia and sleep-related breathing disorders. .137 6 1449 1463 - 30.
Jafari B. Mohsenin V. 2010 Polysomnography. .31 2 287 297 - 31.
N.A. Collop, et al. 2007 Portable Monitoring Task Force of the American Academy of Sleep Medicine.Clinical guidelines for the use of unattended portable monitors in the diagnosis of obstructive sleep apnea in adult patients. Portable Monitoring Task Force of the American Academy of Sleep Medicine. .3 7 737 747 - 32.
Vgontzas A. N. et al. 1994 Sleep apnea and sleep disruption in obese patients. .154 15 1705 1711 - 33.
Resta O. et al. 2001 Sleep-related breathing disorders, loud snoring and excessive daytime sleepiness in obese subjects..25 5 669 675 - 34.
Daltro C. et al. 2007 Prevalence and severity of sleep apnea in a group of morbidly obese patients. .17 6 809 814 - 35.
Shinohara E. et al. 1997 Visceral fat accumulation as an important risk factor for obstructive sleep apnoea syndrome in obese subjects. .241 1 11 18 - 36.
Schäfer H. et al. 2002 Body fat distribution, serum leptin, and cardiovascular risk factors in men with obstructive sleep apnea. .122 3 829 839 - 37.
Vgontzas A. N. et al. 2003 Metabolic disturbances in obesity versus sleep apnoea: the importance of visceral obesity and insulin resistance. .254 1 32 44 - 38.
Kashine S. et al. 2011 Effect of diabetes treatment on changes in sleep-disordered breathing and its related parameters in patients hospitalized with type 2 diabetes mellitus. . in press. - 39.
Idris I. et al. 2009 Obstructive sleep apnoea in patients with type 2 diabetes: aetiology and implications for clinical care. .11 8 733 741 - 40.
Katsumata K. et al. 1991 High incidence of sleep apnea syndrome in a male diabetic population.13 1-2 45 51 - 41.
Einhorn D. et al. 2007 Prevalence of sleep apnea in a population of adults with type 2 diabetes mellitus. .13 4 355 362 - 42.
Rosenberg R. Doghramji P. 2009 Optimal treatment of obstructive sleep apnea and excessive sleepiness. .26 3 295 312 - 43.
Ng A. et al. 2005 Oral appliance therapy for obstructive sleep apnea. .4 6 409 422 - 44.
Hassaballa H. A. et al. 2005 The effect of continuous positive airway pressure on glucose control in diabetic patients with severe obstructive sleep apnea. .9 4 176 180 - 45.
Harsch I. A. et al. 2004 The effect of continuous positive airway pressure treatment on insulin sensitivity in patients with obstructive sleep apnoea syndrome and type 2 diabetes. .71 3 252 259 - 46.
Sundaram S. et al. 2005 Surgery for obstructive sleep apnoea. .19 4 CD001004. - 47.
Lojander J. et al. 1996 Nasal-CPAP, surgery, and conservative management for treatment of obstructive sleep apnea syndrome. A randomized study. .110 1 114 119 - 48.
Holty J. E. Guilleminault C. 2010 Surgical options for the treatment of obstructive sleep apnea. .94 3 479 515 - 49.
Shaw J. E. et al. . 2008 International Diabetes Federation Taskforce on Epidemiology and Prevention. Sleep-disordered breathing and type 2 diabetes: a report from the International Diabetes Federation Taskforce on Epidemiology and Prevention. .81 1 2 12 - 50.
Prabhakar N. R. Kumar G. K. 2010 Mechanisms of sympathetic activation and blood pressure elevation by intermittent hypoxia.174 1-2 156 161 - 51.
Esler M. Eikelis N. 2006 Is obstructive sleep apnea the cause of sympathetic nervous activation in human obesity? .100 1 11 12 - 52.
Drager L. F. et al. 2010 The impact of obstructive sleep apnea on metabolic and inflammatory markers in consecutive patients with metabolic syndrome. .5 8 e12065. - 53.
Sahlman J. et al. Kuopio Sleep. Apnoea Group. 2010 The activation of the inflammatory cytokines in overweight patients with mild obstructive sleep apnoea. .19 2 341 348 - 54.
Romero-Corral A. et al. 2010 Interactions between obesity and obstructive sleep apnea: implications for treatment. .137 3 711 719 - 55.
Follenius M. et al. 1992 Nocturnal cortisol release in relation to sleep structure. .15 1 21 27 - 56.
Henley D. E. et al. 2009 Hypothalamic-pituitary-adrenal axis activation in obstructive sleep apnea: the effect of continuous positive airway pressure therapy. .94 11 4234 4242 - 57.
Vgontzas A. N. Chrousos G. P. 2002 Sleep, the hypothalamic-pituitary-adrenal axis, and cytokines: multiple interactions and disturbances in sleep disorders. .31 1 15 36 - 58.
Lam J. C. et al. 2008 Hypoadiponectinemia is related to sympathetic activation and severity of obstructive sleep apnea. .31 12 1721 1727 - 59.
Wang D. Teichtahl H. 2007 Opioids, sleep architecture and sleep-disordered breathing. .11 1 35 46 - 60.
Bradley T. D. Floras J. S. 2009 Obstructive sleep apnoea and its cardiovascular consequences.373 9657 82 93 - 61.
Rasche K. et al. 2010 Obstructive sleep apnea and type 2 diabetes.15 No. Suppl 2,152 1526 - 62.
Lui M. M. Ip M. S. 2010 Disorders of glucose metabolism in sleep-disordered breathing. .31 2 271 285 - 63.
Reaven G. M. 1993 Role of insulin resistance in human disease (syndrome X): an expanded definition. .44 121 131 - 64.
Wilcox I. et al. 1998 Syndrome Z’: The Interaction of Sleep Apnoea, Vascular Risk Factors and Heart Disease. .53 Supple3 S25 S28 - 65.
Maeda K. et al. 1997 Analysis of an expression profile of genes in the human adipose tissue. .190 2 227 235 - 66.
Matsuzawa Y. et al. 2004 Adiponectin and metabolic syndrome..24 1 29 33 - 67.
Shimomura I. et al. 1996 Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. .2 7 800 803 - 68.
Matsumoto S. et al. 2002 Increased plasma HB-EGF associated with obesity and coronary artery disease. .292 3 781 786 - 69.
Funahashi T. et al. 1999 Role of adipocytokines on the pathogenesis of atherosclerosis in visceral obesity. .38 2 202 206 - 70.
Matsuzawa Y. 2010 Establishment of a concept of visceral fat syndrome and discovery of adiponectin. .86 2 131 141 - 71.
Maeda K. et al. 1996 cDNA cloning and expression of a novel adipose specific collagen-like factor, apMa (Adipose Most Abundant gene transcript 1). .221 2 286 289 - 72.
Scherer P. E. et al. 1995 A novel serum protein similar to C1q, produced exclusively in adipocytes. .270 45 26746 - 73.
Hu E. et al. 1996 AdipoQ is a novel adipose-specific gene dysregulated in obesity. .271 18 10697 - 74.
Nakano Y. et al. 1996 Isolation and characterization of GBP28, a novel gelatin- binding protein purified from human plasma. .120 4 803 - 75.
Arita Y. et al. 1999 Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. .257 1 79 83 - 76.
Okamoto Y. et al. 2000 An adipocyte-derived plasma protein, adiponectin, adheres to injured vascular walls. .32 2 47 50 - 77.
Ouchi N. et al. 2003 Obesity, adiponectin and vascular inflammatory disease. .14 6 561 566 - 78.
S.H. Han et al. 2009 Antiatherosclerotic and anti-insulin resistance effects of adiponectin: basic and clinical studies.52 2 126 140 - 79.
Kishida K. et al. 2011 Visceral adiposity as a target for the management of the metabolic syndrome: A Japanese perspective. . in press. - 80.
Nakagawa Y. et al. 2008 Nocturnal reduction in circulating adiponectin concentrations related to hypoxic stress in severe obstructive sleep apnea-hypopnea syndrome. .294 4 E778 E784 - 81.
Nakagawa Y. et al. 2011 Nocturnal falls of adiponectin levels in sleep apnea with abdominal obesity and impact of hypoxia-induced dysregulated adiponectin production in obese murine mesenteric adipose tissue. . in press. - 82.
Kashine S. et al. 2010 Characteristics of sleep-disordered breathing in Japanese patients with type 2 diabetes mellitus.59 5 690 696 - 83.
Wulan S. N. et al. 2010 Ethnic differences in body composition and the associated metabolic profile: a comparative study between Asians and Caucasians. .65 4 315 319 - 84.
W.Y. Fujimoto, et al. (1999) Visceral adiposity and incident coronary heart disease in Japanese-American men. The 10-year follow-up results of the Seattle Japanese-American Community Diabetes Study. Diabetes Care.11 22 1808 1812 - 85.
Tong J. et al. 2007 Intra-abdominal fat accumulation predicts the development of the metabolic syndrome in non-diabetic Japanese-Americans. .50 6 1156 1160 - 86.
T. Kadowaki, et al. (2006) Japanese men have larger areas of visceral adipose tissue than Caucasian men in the same levels of waist circumference in a population-based study. International Journal of Obesity (London).7 30 1163 1165 - 87.
Fujioka S. et al. 1987 Contribution of intra-abdominal fat accumulation to the impairment of glucose and lipid metabolism in human obesity.36 1 54 59 - 88.
Matsuzawa Y. et al. 1994 Pathophysiology and pathogenesis of visceral fat obesity.24 No. Suppl,S111 S116